Evaluating the Anticancer and Anti‐Angiogenic Efficacy of Bergaptol in 2D and 3D Tumor Microtissue Models Authors: Buse Bekar, Handan Sevim Akan Published: 2026 ABSTRACT ABSTRACTFuranocoumarins are plant‐derived compounds with diverse biological activities and emerging therapeutic potential. This study evaluated the anticancer and anti‐angiogenic properties of bergaptol by using MDA‐MB‐231, HepG2, and HeLa cancer cell lines, as well as HUVEC endothelial cells, with HDFs serving as the healthy control group. Cell viability, apoptosis, cell‐cycle progression, and angiogenesis were evaluated using complementary two‐dimensional (2D) and three‐dimensional (3D) experimental models. Bergaptol exhibited selective cytotoxicity toward cancer and endothelial cells, with no apparent cytotoxicity toward HDFs. Treatment induced apoptosis, disrupted cell‐cycle progression, and suppressed angiogenic activity. In 3D models, bergaptol reduced spheroid viability, diminished spheroid size, and decreased endothelial cell content. An ex vivo assay, the chorioallantoic membrane (CAM) assay, corroborated these observations, demonstrated a substantial inhibition of neovascularization, and further supports its anti‐angiogenic potential. These findings demonstrate that bergaptol exhibits both anticancer and anti‐angiogenic activity in 2D and 3D experimental models supporting further evaluation of bergaptol as a potential anticancer agent.Keywords: angiogenesis, anti‐cancer molecules, bergaptol, furanocoumarins, microtissues Introduction Furanocoumarins are a class of phytochemicals produced by various plant species, historically used in traditional medicine across Eurasia [1]. These compounds are synthesized in response to environmental stress and serve as natural defense agents against pathogens and herbivores [2]. Psoralen and angelicin, representing the linear and angular subclasses, respectively, are among the most studied furanocoumarins [3]. Approximately 65% of anticancer drugs are derived from natural sources, furanocoumarins have gained significant interest for their therapeutic potential [4, 5, 6]. Bergaptol (5‐hydroxypsoralen) is a linear furanocoumarin predominantly present in citrus fruits such as lemons, grapefruits, and bergamots [7]. With a molecular formula of C11H6O4, a molecular weight of 202.16 g/mol, and a half‐life of approximately 8 h in mammalian systems [8, 9], Bergaptol is recognized for its emerging anticancer and anti‐inflammatory properties. It has demonstrated effectiveness in models of glioblastoma, breast, and hepatocellular carcinoma, mainly by triggering apoptosis and cell‐cycle arrest. These effects are mediated through the regulation of STAT3/Bcl‐2, Bax/Bcl‐2, caspase activation, and decreased intracellular ROS, collectively suggesting potential anti‐angiogenic activity [4, 10, 11, 12]. Previous studies suggest that bergaptol‐mediated modulation of STAT3 signaling may influence angiogenic pathways. Additionally, bergaptol inhibits cytochrome P450 enzymes and P‐glycoprotein, suggesting a role in overcoming chemoresistance, and downregulates pro‐inflammatory cytokines such as TNF‐α, IL‐1β, and IL‐6 [12, 13]. Pharmacokinetic data indicate moderate absorption and prolonged plasma retention compared with other coumarins [12, 14]. Recent reports suggest lower phototoxicity associated with bergaptol than with certain linear furanocoumarins [15, 16]. The tumor microenvironment (TME) and tumor‐associated angiogenesis are critical drivers of cancer progression, metastasis, and therapeutic resistance [7]. The TME consists of a dynamic, heterogeneous population of stromal and immune cells that modulate cancer cell morphology, gene expression, and invasive potential [9, 10], while angiogenesis supports tumor growth and dissemination by supplying nutrients and oxygen through neovascularization [8, 9, 10, 12]. Consequently, targeting angiogenesis remains a primary strategy in oncology. Although preclinical drug development routinely relies on two‐dimensional (2D) cell cultures, these models fail to replicate essential features of the TME, including extracellular matrix composition, cell–cell interactions, and oxygen gradients [13]. In contrast, three‐dimensional (3D) multicellular tumor models mimic the structural and functional complexity of in viv o tumors, providing a more physiologically relevant platform for evaluating therapeutic efficacy [14, 15, 16]. To bridge the gap between in vitro screening and mammalian assays, the chick embryo chorioallantoic membrane (CAM) assay serves as an established in vivo‐like model [17]. Due to its high vascular density and rapid development, the CAM allows direct visualization and quantification of neovascularization, offering a cost‐effective and ethically less restrictive alternative for the preliminary evaluation of anti‐angiogenic and antitumor molecules [18]. The present study aimed to investigate the anticancer and anti‐angiogenic potential of bergaptol using MDA‐MB‐231, HeLa, and HepG2 cancer cell lines. The MDA‐MB‐231, HeLa, and HepG2 cell lines were selected as representative models of breast, cervical, and liver cancers, enabling a broader evaluation across distinct oncological contexts. Given the high incidence and mortality rates of these malignancies, employing such models is crucial for advancing anticancer research and guiding more detailed therapeutic strategies. Initially, we assessed bergaptol's cytotoxic, pro‐apoptotic, and anti‐proliferative effects under conventional 2D culture conditions. To more closely mimic the complexity of the in vivo tumor microenvironment, we developed 3D multicellular tumor microtissues composed of human dermal fibroblasts (HDF), human umbilical vein endothelial cells (HUVEC), and cancer cells. These models provided a physiologically relevant platform to evaluate bergaptol's effects on tumor vascularization and cell viability. Additionally, a chick CAM assay was conducted to further validate its anti‐angiogenic activity in an in vivo‐like setting. To the best of our knowledge, this is the first study to systematically evaluate bergaptol's dual anticancer and anti‐angiogenic properties within a 3D co‐culture system using an ex vivo assay, which may contribute to a better understanding of its therapeutic relevance and support future investigations in this area. Results and Discussion Dose‐ and Time‐Dependent Cytotoxicity of Bergaptol MTT assay showed a significant, concentration‐dependent decrease in cell viability following bergaptol treatment in HeLa, MDA‐MB‐231, HepG2, and HUVEC cells compared to the untreated control group. Following bergaptol treatment, inhibition in cell viability was observed starting from 100 µM concentration at 24 h; however, this effect became more pronounced at 48 h, showing statistically significant reductions, particularly in HeLa and MDA‐MB‐231 cell lines. By 72 h posttreatment, cell viability was strongly inhibited even at the lowest concentration. In contrast, in HDF cells (the healthy control cells), an increase in cell viability was observed following bergaptol treatment, especially at higher concentrations, which were statistically significant compared to the control (* p≤0.05) (Data not shown). Based on these findings, a 48‐h treatment period was selected for subsequent experiments. At 48 h, 100 µM bergaptol significantly reduced viability in HeLa and MDA‐MB‐231 cells (****p ≤ 0.0001), while HepG2 cells showed a significant response only at 150 µM (***p ≤ 0.0002) (Figure 1). HUVEC also exhibited a moderate but significant reduction in viability at 100 µM (*p ≤ 0.05). In contrast, HDF cells showed a concentration‐dependent increase in viability (*p ≤ 0.05), supporting the selective cytotoxicity of bergaptol. Bergaptol reduces cell viability in a dose‐ and time‐dependent manner. (a) MTT assay results show decreased viability in HeLa, MDA‐MB‐231, HepG2, and HUVEC cells following bergaptol treatment in a concentration‐dependent manner. HDF cells showed increased viability at higher concentrations. (b) MTT assay‐based % cell viability of HeLa, MDA‐MB‐231, and HepG2 cells after bergaptol treatment. Graphs represent the mean percentage of cell viability values relative to the control group. Data are presented as mean ± SD. Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test, with a significance threshold of p<0.05. Statistical significance: *p ≤ 0.05, **p ≤ 0.009, ***p ≤ 0.0002, ****p ≤ 0.0001 (n = 6). Following 48 h of bergaptol exposure, the IC50 values were estimated to be 85 µM in HeLa cells, 98 µM in HepG2 cells, and 100 µM in MDA‐MB‐231 cells. These findings demonstrate that bergaptol exerts growth‐inhibitory effects within a similar concentration range across the evaluated cancer cell lines. The comparative analysis reveals that HeLa cells are the most sensitive to the treatment, showing a sharp decline in viability across all doses. HepG2 cells follow a similar trend, particularly reaching significant cytotoxicity at 150 µM. In contrast, MDA‐MB‐231 cells exhibit a more resistant phenotype, maintaining approximately 60% viability even at the highest concentration (150 µM) (Figure 1b). Doxorubicin was used as a positive control, and treatment with Doxorubicin markedly reduced viability across all tested cell types, including healthy control cells. Bergaptol did not induce detectable cytotoxicity in the healthy control group, indicating a preferential activity toward malignant cells. Selective Cytotoxic Effects Validated by AO/PI Staining AO/PI staining was conducted on HeLa, MDA‐MB‐231, HepG2, HUVEC, and HDF cells subjected to bergaptol treatment for 24, 48, 72 h. A marked concentration‐ and time‐dependent decrease in cell viability was accompanied by an increase in cell death, starting from the lowest concentration of bergaptol in cancer cells (Figure 2). The most pronounced effects were seen at 48 h. In MDA‐MB‐231 cells, cell death peaked at 150 µM, while in HeLa cells, viability was suppressed even at 25 µM, with maximal effect at 100 µM. HepG2 cells showed substantial viability loss at 150 µM. Similar cytotoxic effects were also noted in HUVEC, with cell viability suppressed 100 and 150 µM. HDF cells remained unaffected, confirming the selective action of bergaptol. AO/PI staining reveals selective cytotoxicity of bergaptol in cancer cells. Fluorescence microscopy images of HeLa, MDA‐MB‐231, HepG2, HUVEC, and HDF cells after bergaptol treatment (Olympus IX70, 10×, excitation: 460–490 nm, scale bar: 200 µm). Cell death was observed in all cancer cell lines starting from the lowest concentration, and a marked increase in non‐viable cells was observed at the highest concentration. No cytotoxicity was observed in HDF cells. Orange/red cells indicate late apoptotic or necrotic cells (n = 3). Bergaptol Induces Dose‐Dependent Apoptosis in Cancer and Endothelial Cells Annexin V‐FITC/PI staining demonstrated a concentration‐dependent induction of apoptosis in MDA‐MB‐231, HeLa, HepG2, and HUVEC cells after 48 h of bergaptol treatment (Figure 3). In MDA‐MB‐231 cells, late apoptosis reached 70.16% at 100 µM, with viable cells reduced to 7.56% (p ≤ 0.0001). In HeLa cells, late apoptotic cells increased from 16.75% at 25 µM to 84.88% at 100 µM (p ≤ 0.0001). HepG2 cells showed a marked increase in early apoptosis, rising from 0.81% to 40.92% (p ≤ 0.0001), and late apoptosis increased from 2.66% to 31.60% (p ≤ 0.0001), suggesting initiation of the apoptotic cascade. HUVEC exhibited a modest apoptotic response, with late apoptosis reaching 19.30% at 100 µM (p≤0.003). A marked increase in late apoptotic populations was observed across all cell lines, HepG2 cells demonstrated the greatest increase in early apoptotic cells. Bergaptol induces apoptosis in cancer and endothelial cells. (a) Representative dot plot showing Annexin V‐FITC/PI staining for apoptotic cell detection; (b) Quantitative analysis of apoptosis based on the percentage of early and late apoptotic cells, presented as mean ± SD from three independent experiments. Annexin V‐FITC/PI flow cytometry analysis after 48 h of bergaptol treatment in HeLa, MDA‐MB‐231, HepG2, and HUVEC cells. A concentration‐dependent increase in apoptotic cells and a decrease in viable cells were observed. A minimum of 15 000 events were analyzed per group (CytoFLEX LX, Beckman Coulter). Data are presented as mean ± SD. Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test, with a significance threshold of p<0.05. Statistical significance: *p ≤ 0.02, **p ≤ 0.005, ***p ≤ 0.0003, ****p ≤ 0.0001 (n = 3). Colony Formation Inhibited by Bergaptol Indicates Long‐Term Antiproliferative Effect To assess the long‐term effects of bergaptol, colony formation assays were conducted using HeLa, MDA‐MB‐231, and HepG2 cell lines. The results showed that at higher concentrations, colony formation was completely suppressed across all repeated experiments (data not shown). Treatment with 25 µM, bergaptol completely inhibited colony formation in HeLa and MDA‐MB‐231 cells, while only a low number of colonies were observed in HepG2 cells (Figure 4). The plating efficiency (PE) and survival fraction (SF) were also calculated after the colony formation assay. In HepG2 cells, the control group showed a PE of 38.33%, corresponding to 230 colonies formed from 600 seeded cells. Treatment with 25 µM bergaptol reduced the PE to 3.33%, with a SF of 0.087. Similarly, HeLa cells exhibited a PE of 21.67% in the untreated control group, which decreased to 0.50% after treatment, yielding an SF of 0.023. In MDA‐MB‐231 cells, the control group displayed a PE of 25.00%, whereas no colonies were detected after bergaptol exposure, resulting in an SF of 0.00. These findings demonstrate that bergaptol effectively suppresses the clonogenic capacity of cancer cells and impairs their long‐term proliferative potential. Bergaptol suppresses colony formation in cancer cells. (a) Graphical representation of colony formation before and after treatment with bergaptol, (b) Representative image of colony formation in the control group. Complete inhibition of colony formation was observed in HeLa and MDA‐MB‐231 cells; HepG2 cells formed only a few colonies. Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test with GraphPad Prism software. Data are presented as mean ± SD. Statistical significance ****p ≤ 0.0001 (n = 3). Bergaptol Inhibits DNA Synthesis and S‐Phase Progression in Cancer Cells BrdU incorporation analysis revealed a concentration‐dependent decrease in proliferative activity following bergaptol treatment across all tested cancer cell lines. Microscopic evaluation demonstrated a marked reduction in BrdU‐positive nuclei at both 25 and 50 µM concentrations, consistent with the quantitative data showing a significant decline in the number of BrdU‐positive cells compared with controls (Figure 5). The inhibitory effect was most pronounced in MDA‐MB‐231 and HeLa cells, indicating that bergaptol effectively impairs DNA synthesis and cell proliferation. Bergaptol inhibits DNA synthesis in cancer cells. BrdU incorporation assay showing reduced S‐phase entry in HeLa, MDA‐MB‐231, and HepG2 cells after treatment with 25 and 50 µM bergaptol. A decrease in the number of cells entering the S phase was observed in all cancer cell lines. (a) Representative images of BrdU‐labeled cells; (b) Quantification of BrdU‐positive nuclei. (Olympus IX70, 10×, scale bar: 200 µm). Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test with GraphPad Prism software. Data are presented as mean ± SD. Statistical significance **p ≤ 0.001, ***p ≤ 0.0005, ****p ≤ 0.0001 (n = 3). Differential Cell Cycle Arrest Induced by Bergaptol in Cancer Cells Flow cytometric analysis revealed cell line–specific patterns of cell‐cycle arrest (Figure 6). After 48 h of bergaptol treatment, distinct alterations in cell‐cycle distribution were observed across the different cancer cell lines. In HeLa cells, a pronounced accumulation in the G0–G1 phase was accompanied by a reduction in the S and G2–M phases. HepG2 cells exhibited a similar profile, with increased G0–G1 and decreased S and G2–M fractions. In contrast, MDA‐MB‐231 cells displayed a reduction in G0–G1 and an additional increase in S and G2–M phases. Bergaptol induces cell cycle arrest in a cell line‐specific manner. (a) Representative histogram of DNA content showing cell cycle phases (G0/G1, S, G2/M); (b) Quantitative analysis of cell cycle distribution represented as mean ± SD from three independent experiments. Flow cytometry analysis of cell cycle distribution in HeLa, MDA‐MB‐231, and HepG2 cells after 48 h of bergaptol treatment. HeLa and HepG2 cells showed G0–G1 arrest, while MDA‐MB‐231 cells exhibited increased S and G2–M phase populations. A minimum of 15 000 events were analyzed per group (CytoFLEX LX, Beckman Coulter). Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test with GraphPad Prism software. Data are presented as mean ± SD. Statistical significance: *p ≤ 0.01, **p ≤ 0.001, ***p ≤ 0.0002, ****p ≤ 0.0001 (n = 3). Bergaptol Disrupts Spheroid Structure and Reduces Viability in 3D Cultures We used calcein AM/PI staining to assess viability and spheroid morphology/size following treatment with 50 and 100 µM bergaptol (Figure 7a). The results demonstrated a significant reduction in cell viability, as evidenced by a decreased spheroid diameter and diminished green fluorescence after bergaptol treatment. Notably, after 72 h of bergaptol treatment, the spheroids exhibited marked disintegration, morphological deterioration, and a further reduction in their diameters, indicating extensive cell death and structural damage. Quantitative measurements confirmed that bergaptol significantly reduced spheroid size beginning at 24 h, with both 50 and 100 µM concentrations producing substantial decreases compared with time‐matched controls. The most pronounced growth inhibition was observed at 72 h, where 100 µM bergaptol effectively prevented the natural expansion of tumor spheroids, maintaining significantly smaller diameters across all three cell lines (Figure 7b). Bergaptol reduces viability and disrupts structure in 3D cancer spheroids. (a) Calcein AM/PI staining of microtissues composed of HeLa/MDA‐MB‐231/HepG2 + HUVEC + HDF cells after bergaptol treatment. Green fluorescence indicates viable cells. A reduction in spheroid diameter and viability was observed especially after 72 h (Olympus IX70, 10×, excitation: 460–490 nm, scale bar: 200 µm) (n = 3). (b) Bergaptol‐induced changes in tumor spheroid diameter (µm). Quantitative analysis of spheroid diameters measured before and after bergaptol treatment for 24/48/72 h. Measurements were performed using ImageJ software (n = 3). Significant differences between the bergaptol‐treated groups and the control group were determined using the one‐way ANOVA test with GraphPad Prism software. Data are presented as mean ± SD. Statistical significance: *p ≤ 0.05, **p ≤ 0.009, ***p ≤ 0.0002, ****p ≤ 0.0001. Bergaptol Reduces Endothelial Cell Content in Microtissues The CFSE data revealed that under normal conditions, the percentage of HUVEC in untreated cancer microtissues was 53.69%, this proportion decreased to 45.46%, corresponding to an 8.23% reduction in CFSE‐labeled endothelial cells after bergaptol treatment (Figure 8a). This decline indicates a reduction in the number of endothelial cells within the microtissue cell communities compared to the control. (a) Bergaptol reduces endothelial cell content in microtissues. Flow cytometry analysis of CFSE‐labeled HUVEC in spheroids. Bergaptol treatment reduced the proportion of CFSE‐positive endothelial cells by 8.23%. A minimum of 15 000 events were analyzed per group (CytoFLEX LX, Beckman Coulter) (n = 3). (b) Time‐dependent effects of bergaptol on endothelial integrity in spheroids. Confocal microscopy images of spheroids treated with bergaptol on day 0 or day 6. Green: CFSE‐labeled HUVEC; Blue: DAPI‐stained nuclei (HUVEC + HDF + HeLa). Early treatment disrupted spheroid formation and eliminated endothelial cells; delayed treatment preserved partial endothelial structure (Zeiss LSM980, 10X, scale bar: 100 µm), (n = 3). Confocal microscopy results also revealed a time‐dependent reduction in endothelial cell presence within spheroids (Figure 8b). On day 0 after seeding, spheroid structure was impaired, and endothelial cells were eliminated in the bergaptol‐treated group. In day 6 treatment group, endothelial cells persisted but in reduced numbers, and the remaining spheroid structure showed signs of viability loss. These findings align with earlier observations of bergaptol's cytotoxic effects on endothelial cells and showed that prolonged exposure compromises endothelial integrity and spheroid architecture. Bergaptol Suppressed Angiogenesis in the CAM Assay The effects of bergaptol on angiogenesis were further evaluated using the CAM assay at three different concentrations (150, 500, and 1000 µM). Baseline images obtained before treatment revealed comparable vascular density and morphology among all experimental groups. Following 48 h of incubation, clear differences in vascular development emerged, revealing concentration‐dependent alterations in angiogenic progression. (Figure 9). Bergaptol‐induced changes in angiogenesis in the CAM assay. (a) Representative CAM images of eggs treated with 150, 500, and 1000 µM bergaptol on day 0 and day 2. (b) Quantitative assessment of total vessel length, number of nodes, and number of meshes using the Angiogenesis Analyzer plugin in ImageJ. negative control (PBS containing 1% DMSO); positive control (40 µM sorafenib). Data are presented as mean ± SD. Significant differences between the bergaptol‐treated groups and the control group were determined using the t‐test, with a significance threshold of p < 0.05. Statistical significance: *p ≤ 0.05, **p ≤ 0.009, ***p ≤ 0.0002, ****p ≤ 0.0001 (n = 6). Quantitative analysis of total vessel length revealed a marked reduction in all bergaptol‐treated groups compared with baseline conditions. Across the tested concentrations, the decrease approached 50%, underscoring a substantial inhibitory effect on vascular growth. In contrast, the negative control group preserved its vascular architecture, showing only a slight increase in vessel length during incubation, whereas the positive control group exhibited a reduction by the end of the experiment. A similar pattern was observed in the number of branching points (nodes), with bergaptol treatment inducing a pronounced decline after 48 h, thereby indicating a considerable disruption of vascular network formation and complexity. The number of vascular meshes, representing enclosed capillary structures, was likewise diminished following bergaptol exposure. While the negative control group demonstrated an increase in mesh formation consistent with normal vascular development, the positive control group showed a decline. Collectively, findings from the CAM assay demonstrate that bergaptol suppresses angiogenesis by impairing vessel elongation, branching, and capillary network organization. Discussion Bergaptol, a naturally occurring furanocoumarin predominantly found in citrus species, has been previously reported to exert a wide spectrum of biological activities [12]. The present study extends this knowledge by providing mechanistic insight into its anticancer and anti‐angiogenic potential across both conventional 2D systems, physiologically relevant 3D tumor microtissue models, and an ex vivo CAM assay. The cell line–specific cytotoxicity observed in cancer and endothelial cells, alongside the absence of toxicity in healthy fibroblasts, suggests that bergaptol may preferentially target signaling pathways that are dysregulated in malignant and angiogenic cell populations. The observed differential sensitivity, where HeLa and HepG2 cells exhibited higher vulnerability compared to MDA‐MB‐231, might be attributed to varying expression levels of target signaling molecules or differences in the metabolic processing of furanocoumarins between these specific cancer types. In HeLa cells, bergaptol treatment induced a sharp decline in viability beginning at low concentrations, accompanied by marked apoptosis, G0–G1 cell cycle arrest, and complete suppression of colony formation, highlighting their high sensitivity to treatment. HepG2 cells exhibited significant cytotoxicity only at higher concentrations, with increases in early and late apoptotic populations, reduced clonogenic capacity, and G0–G1 arrest, revealing a more resistant but still responsive phenotype. MDA‐MB‐231 cells showed moderate resistance in viability assays, yet displayed strong late apoptotic responses, complete inhibition of colony formation, impaired DNA synthesis, and accumulation in S and G2–M phases, reflecting disruption of proliferative and survival pathways. HUVEC endothelial cells also showed significant viability loss and apoptosis, with reduced presence in 3D spheroids. HDF cells remained unaffected, confirming bergaptol's preferential activity against malignant cells. Cancer and endothelial cells are highly dependent on constitutively activated survival and proliferation pathways, whereas normal fibroblasts rely on these pathways to a far lesser extent [19, 20, 21]. We demonstrate this pronounced sensitivity of cancer and endothelial cells to bergaptol, supported by previous reports demonstrating that bergaptol promotes apoptosis and inhibits proliferation in glioma cells [11, 13]. The observed disruption in cell cycle progression further supports this mechanistic framework, as G0/G1 arrest and reduced S‐phase entry indicate impaired DNA synthesis and checkpoint activation. Furanocoumarins are known to interact with DNA and interfere with replication processes, leading to replication stress and activation of cell cycle checkpoints [11, 22, 23, 24]. In this context, bergaptol may induce cytostatic effects by triggering DNA damage responses or inhibiting cyclin‐dependent regulatory mechanisms, thereby limiting proliferative capacity, particularly in rapidly dividing cancer cells. Although bergaptol exerted IC50 values within the higher micromolar range, its profile is distinguished by the absence of cytotoxicity toward non‐malignant fibroblasts. In contrast to doxorubicin, which displays potent activity at low concentrations but is limited by severe systemic toxicities and off‐target damage [25], bergaptol specifically impaired malignant and endothelial cells while preserving normal fibroblast viability. These findings support bergaptol as a promising natural derivative with a safety profile, warranting further molecular and in vivo studies to validate its anticancer potential. Time‐dependent variations in efficacy may reflect pharmacokinetic characteristics of potential anticancer and anti‐angiogenic agents. Animal studies have reported an approximate half‐life of 8 h for bergaptol [12, 26], suggesting that biological activity could diminish at extended incubation times, especially at lower concentrations. Nevertheless, the persistence of cytotoxic effects at 48 and 72 h implies either sustained intracellular activity, the formation of active metabolites, or cumulative effects arising from prolonged exposure. Differences in cell doubling times among the tested cell types may further influence susceptibility, with faster proliferating cells being inherently more vulnerable to agents that disrupt cell cycle progression. A key strength of this study lies in the use of a multicellular 3D tumor microtissue model incorporating cancer cells, fibroblasts, and endothelial cells. Such models more accurately reflect cell–cell interactions, extracellular matrix influences, and angiogenic processes than traditional monolayer cultures [26, 27]. The preservation of bergaptol activity in multicellular microtissues is noteworthy because therapeutic responses often differ substantially between 2D and 3D systems. The inclusion of fibroblasts and endothelial cells creates a more physiologically relevant microenvironment that partially reproduces stromal interactions present in solid tumors. The ability of bergaptol to maintain its anticancer efficacy in this complex environment suggests that it can overcome microenvironment‐mediated resistance mechanisms, which often limit the translational relevance of 2D findings. Notably, the reduction in endothelial cell content within 3D microtissues highlights a potential anti‐angiogenic mechanism. Tumor angiogenesis is a critical driver of tumor growth and metastatic dissemination [28, 29, 30], and targeting vascular support has become a central strategy in anticancer therapy. The observed impairment of endothelial cell viability and vascular organization implies that bergaptol may interfere with angiogenesis‐associated signaling, potentially involving VEGF‐dependent or inflammatory pathways. Our findings also support that multicellular microtissue platforms are particularly well suited for assessing such anti‐angiogenic effects [31] Angiogenesis is widely recognized as a fundamental hallmark of cancer, playing a pivotal role in tumor growth, progression, and metastasis. Accordingly, the inhibition of neovascularization has emerged as a critical strategy in anticancer drug development [32, 33, 34]. In our study, direct application of bergaptol to the vascularized region of the CAM resulted in a significant reduction in blood vessel formation, demonstrating a pronounced anti‐angiogenic effect. The CAM assay is broadly accepted as a reliable model for evaluating vascular responses due to its highly developed and accessible vascular network [17]. The observed decrease in vessel density suggests that bergaptol interferes with angiogenic processes essential for the establishment and maintenance of new vasculature. Together with its cytotoxic and pro‐apoptotic effects in cancer cells and its ability to reduce HUVEC viability in endothelial microtissues, the anti‐angiogenic activity observed in the CAM assay provides complementary evidence supporting the multifaceted anticancer potential of bergaptol. The substantial reduction in vessel number following bergaptol treatment further underscores its potential as an anti‐angiogenic potential. To the best of our knowledge, this is the first study to evaluate bergaptol in a physiologically relevant 3D model and ex vivo model that mimics the tumor microenvironment. Bergaptol induced significant cytotoxicity, apoptosis, and cell cycle arrest in multiple cancer cell lines, while sparing healthy fibroblasts, highlighting its distinctive potential. Importantly, its efficacy was preserved in 3D multicellular tumor microtissues, where it disrupted spheroid integrity and reduced endothelial cell content, underscoring its ability to target both tumor cells and the tumor vasculature. Furthermore, the marked inhibition of vascular development observed in the CAM model confirmed its anti‐angiogenic potential and demonstrated its capacity to interfere with tumor‐associated neovascularization. Finally, combination therapies involving bergaptol and clinically approved chemotherapeutics may also reveal synergistic interactions, potentially enhance treatment outcomes, and overcome drug resistance. Such strategies could pave the way for the development of more effective, targeted, and less toxic cancer therapies. Conclusions This study provides the first evaluation of bergaptol in physiologically relevant 3D co‐culture systems and an ex vivo CAM model that mimics the tumor microenvironment. Our results showed that bergaptol exerts its anticancer effects through coordinated modulation of proliferative, apoptotic, and angiogenic processes. Rather than functioning solely as a cytotoxic compound, bergaptol appears to impair tumor progression through multiple complementary mechanisms, including the induction of apoptosis, loss of membrane integrity, disruption of cell cycle progression, and inhibition of angiogenic processes required for tumor vascularization. These mechanistic insights strengthen the rationale for further molecular investigations and the importance of bergaptol as a promising candidate for future research in cancer therapy. Despite these promising results, this study has certain limitations, particularly the reliance on in vitro models which cannot fully replicate the complex physiological environment of a living organism. Therefore, future studies should focus on comprehensive molecular and signaling pathway analyses to elucidate the mechanism underlying bergaptol's anticancer and anti‐angiogenic effects. Additionally, transitioning bergaptol to clinical use presents potential translational challenges, including the optimization of delivery systems and the assessment of its long‐term metabolic stability. In this context, in vivo models will be essential to assess its pharmacokinetics, bioavailability, and therapeutic efficacy of complex biological systems. Experimental Section Materials and Methods Chemicals and Cell Lines In this study, HDF (human dermal fibroblasts, ATCC PCS‐201‐01), HUVEC (human umbilical vein endothelial cells, ATCC PCS‐100‐013, RRID:CVCL_9Q53), MDA‐MB‐231 (breast cancer, ATCC CRM‐HTB‐26), HepG2 (liver cancer, ATCC HB‐8065), and HeLa (cervical cancer, ATCC CRM‐CCL‐2, RRID:CVCL_0030) cell lines were used. Initially, each cell line was expanded and cryopreserved for subsequent experimental procedures. For all experimental studies, bergaptol (Cat. No: 486‐60‐2, Macklin) was dissolved in dimethyl sulfoxide (DMSO) to prepare a stock solution at a concentration of 10 mg/mL. The chemicals used for experiments are as follows, tetrazolium salt 3‐[4,5‐dimethylthiazol‐2‐yl]‐ 2,5‐diphenyl tetrazolium bromide (Cat. no: M5655, Sigma Aldrich, Germany), DMEM or DMEM High Glucose medium containing two mM l‐glutamine, 10% fetal bovine serum and 100 IU/mL Penicillin–Streptomycin (Cat. no: L0092, Cat no: S0615, Cat. no: L0022; Biowest, USA), Crystal violet (Cat. no: 101408, Merck), Isopropyl alcohol (Cat. No: 109634, Merc Milipore), Acridine orange (AO) (Cat. no: 65‐61‐2, Sigma‐Aldrich, Germany), Propidium Iodide (PI) (Cat. no: 25535‐16‐4, Sigma‐Aldrich, Germany), Agarose low EEO (Applichem), and Doxorubicin hydrochloride (D1515, Sigma‐Aldrich, Germany). Cell Viability and Apoptosis Analysis MTT Assay and AO/PI Staining Cell viability was assessed using the MTT assay to evaluate the cytotoxic effects of bergaptol and to determine an effective dose for subsequent experiments. HeLa, MDA‐MB‐231, HepG2, HUVEC, and HDF cells were seeded into 96‐well plates at a density of 1 × 104 cells per well and incubated for 24 h under standard culture conditions (37°C, 5% CO2). Cells were treated with bergaptol at concentrations of 25, 50, 100, and 150 µM for 24, 48, and 72 h, with all concentrations tested in six independent replicates. Doxorubicin (10 µM) was used as a positive control due to its well‐documented cytotoxic and apoptosis‐inducing effects in a variety of cancer cell models at micromolar concentrations [35, 36]. Following treatment, MTT reagent was added and incubated for 4 h. The resulting formazan crystals were solubilized using acidic isopropanol, and absorbance was measured at 570 nm using a microplate reader. (EZ Read 400, Biochrom, UK). Comparisons between the control and treatment groups were statistically analyzed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). Cell morphology was simultaneously monitored using an inverted microscope (IX70, Olympus, Japan). Finally, treatment‐dependent differences among the cell lines were further evaluated by calculating percentage cell viability relative to the control and analyzing these data using one‐way ANOVA. Acridine orange/propidium iodide (AO/PI) dual staining was performed to assess viable and non‐viable cells. After each incubation period, cells were washed with PBS and stained with a 1:1 mixture of AO and PI for 20 s. Following two additional PBS washes, fluorescent images were taken using a fluorescence microscope (Olympus, Japan; excitation/emission: 460–490 nm / 510–550 nm). Each experiment was repeated three times. Annexin V‐FITC/Propidium Iodide Labeling Annexin V/PI staining was used to analyze apoptotic and necrotic cell death. HepG2, HeLa, MDA‐MB‐231, and HUVEC cells were seeded in 6‐well plates (2–4 × 105 cells/well) and treated with bergaptol at concentrations of 25, 50, and 100 µM for 48 h. All concentrations were tested in three independent replicates. After treatment, apoptosis was assessed using an Annexin V/PI kit (Cat no: 640914, Biolegend) and analyzed by flow cytometry according to the manufacturer's instructions. Briefly, the cells were washed twice with binding buffer, and 5 µL of FITC Annexin V / 10 µL of PI were added to 100 µL of the cell suspension. After 15 min of incubation in the dark, flow cytometry was used to assess the level of apoptosis in the cells. Minimum 15 000 cells were analyzed in each group using a Beckman Coulter Life Sciences CytoFLEX LX Flow Cytometer. Comparisons between the control and treatment groups were statistically analyzed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). Colony Formation Assay To assess the long‐term antiproliferative effects of bergaptol, colony formation assays were performed using HeLa, MDA‐MB‐231, and HepG2 cells, previously described [37]. Briefly, cells were seeded in 6‐well plates and treated with bergaptol at concentrations of 25, 50, 100, and 150 µM. After treatment, cells were cultured under standard conditions for 10–14 days until visible colonies formed. Colonies were fixed with cold methanol and stained with 0.5% crystal violet. The images were captured using an inverted microscope (IX70, Olympus, Japan). Colony numbers were quantified using ImageJ software. All concentrations were tested in three independent replicates, and each experiment was repeated three times. To quantitatively assess the clonogenic capacity of the cells after bergaptol treatment, plating efficiency (PE) and survival fraction (SF) were calculated. PE was defined as the percentage of seeded cells that retained the ability to form colonies, whereas SF was calculated by normalizing the PE of the treated groups to that of the corresponding untreated control. These parameters were used to evaluate the effect of bergaptol on the long‐term survival of cancer cells. Calculations were performed using the following equations: PE (%) = (number of colonies formed/number of cells seeded) × 100, and SF = PE of treated group/PE of control group, as previously described [38, 39]. Cell Cycle Analysis BrdU İncorporation Assay MDA‐MB‐231, HepG2, and HeLa cells were seeded in 96‐well plates and labeled with BrdU (Abcam, Cat. No. ab125306) following bergaptol treatment. Cells were incubated with BrdU for 24 h, followed by immunocytochemical staining, and were subsequently imaged (Olympus IX70, Japan). ImageJ software was used to count BrdU‐positive and BrdU‐negative nuclei in five randomly selected fields per well. All concentrations were tested in three replicates, and each experiment was repeated three times. The data were calculated as the means of all cells counted across five independent fields. Comparisons between the control and treatment groups were statistically analyzed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). CytoPhase Violet Staining CytoPhase Violet (BioLegend, Cat. No. 425701) labeling was used to evaluate the impact of bergaptol on cell proliferation and cell cycle progression. HepG2, HeLa, and MDA‐MB‐231 cells were treated with bergaptol at concentrations of 25, 50, and 100 µM for 48 h. All concentrations were tested in three independent replicates and each experiment was repeated three times. After trypsinization and centrifugation, cells were resuspended in culture medium at a density of 0.5–1 × 106 cells/mL. CytoPhase Violet dye was added to the suspension (5 µM for 1:1000 dilution) and incubated at 37°C for 90 min. The samples were then analyzed using flow cytometry (Beckman Coulter, CytoFLEX LX). Comparisons between the control and treatment groups were statistically analyzed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). Formation Microtissues and Assessment of Angiogenesis Microtissues were formed by using Petri Dish molds (Sigma, Z764019‐6EA). An agar solution was prepared and solidified; the agar blocks were carefully removed from the molds and placed into 12‐well cell culture plates. A serum‐free medium was then added to each well, and the plates were incubated for 15 min to allow the agar to hydrate properly. Following this incubation, the medium was aspirated, and 100 µL of a cell suspension consisting of 750 HUVEC, 750 HDF, and 1500 HeLa/ MDA‐MB‐231/ HepG2 cells was added to each well. The plates were incubated at 37°C for 1 h, during which cells spontaneously formed clusters within the homogeneous spaces created by the agar molds. Spheroid formation was monitored daily, and on the 7th day, the microtissues were treated with bergaptol at concentrations of 50 and 100 µM. Calcein AM‐Propidium Iodide Staining Calcein AM/PI staining is used to assess cell viability and determine the size of spheroids in 3D cultures. After 48 h of bergaptol treatment, the medium was aspirated, and a 100 µL mixture of Calcein AM/PI was added to each well. The plates were incubated for 30 min at 37°C, followed by microtissue imaging under fluorescence microscopy (Olympus, Japan; 10× objective, excitation: 460–490 nm). All concentrations were tested in three independent replicates and each experiment was repeated three times. The spheroid diameters were measured in all groups using ImageJ software and presented graphically. Subsequently, spheroid diameter comparisons between the control and treatment groups were statistically analyzed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). CFSE Labeling of Endothelial Cells for Analyzing Angiogenesis: Flow Cytometry and Confocal Microscopy After analyzing the previous experimental procedures, HeLa cells were identified as the most responsive cancer cell line to bergaptol treatment. Therefore, HeLa cells were selected as the representative cancer cells in microtissue studies and were used in the ongoing experiments. HUVEC were labeled with CFSE (BioLegend, Cat. No. 423801) and co‐cultured with HDF and HeLa cells following the microtissue protocol. Experimental groups included: (1) Day 0 treatment (bergaptol added at day 0 microtissue formation), (2) Day 6 treatment, and (3) untreated control. On day 7, nuclei were stained with DAPI and visualized using confocal microscopy (Zeiss LSM980, 10X). Additionally, CFSE‐labeled HUVEC were quantified by flow cytometry to assess endothelial cell incorporation and angiogenic activity. All concentrations were tested in three replicates and each experiment was repeated three times. Chorioallantoic Membrane (CAM) Angiogenesis Assay The anti‐angiogenic activity of bergaptol was evaluated using the CAM assay in fertilized chicken eggs. Fertilized eggs were incubated at 37.5°C ± 0.5°C and 70%–80% relative humidity for 5 days. On day 5 of incubation, the pointed end of each egg was carefully abraded using a sterile scalpel, and approximately 5–6 mL of albumin was aspirated with a sterile syringe to facilitate the detachment of the CAM from the eggshell and the formation of an artificial air sac. On the following day, a window was aseptically opened in the eggshell, embryo viability was confirmed by visual inspection, and the opening was resealed with sterile surgical tape before the eggs were returned to the incubator. On embryonic day 8, sterile silicone rings were placed on highly vascularized regions of the CAM, and baseline images were acquired. Higher doses were applied in the CAM assay to ensure effective tissue penetration and overcome the physiological clearance inherent to the ex vivo system. Given the inherent complexity and vascular richness of the CAM model, elevated doses are often required to elicit observable inhibitory effects on neovascularization, thereby providing a more reliable assessment of the compound's anti‐angiogenic potential. Subsequently, 100 µL of bergaptol solution was administered within each ring at final concentrations of 150, 500, and 1000 µM. The negative control group received phosphate‐buffered saline (PBS) supplemented with 1% dimethyl sulfoxide (DMSO). Sorafenib (40 µM) was used as a positive control due to its established anti‐angiogenic properties and its widespread use in experimental angiogenesis studies [40]. Following treatment, the eggs were returned to the incubator and maintained under the same conditions for an additional 48 h. The experiment was terminated on embryonic day 12 (ED12), before the developmental stage at which the chick embryo is generally considered capable of nociception; therefore, according to commonly accepted CAM assay guidelines, ethical approval for animal experimentation was not required [41, 42]. At the end of the incubation period, CAM images were captured for analysis. Each experimental group consisted of six independent eggs (n = 6). Quantitative evaluation of the vascular network was performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA) with the Angiogenesis Analyzer plugin. The analyzed parameters included total vessel length, number of branching points (nodes), and number of bounded vascular meshes within the selected region of interest. These parameters were used to assess the effects of bergaptol on angiogenesis and vascular network organization. Statistical Analysis Statistical analyses were performed using GraphPad Prism 8.0.2 (GraphPad Software Inc., San Diego, CA, USA). Data are presented as mean ± standard deviation (SD) from at least three independent experiments (n = 3). The normality of data distribution was assessed using the Shapiro–Wilk test. For normally distributed data, significant differences among multiple groups were determined using one‐way ANOVA followed by Tukey's HSD or Bonferroni post‐hoc tests for multiple comparisons. For non‐parametric datasets, Kruskal–Wallis and Mann–Whitney U tests were employed. A p‐value of p < 0.05 was considered statistically significant for all analyses. Author Contributions Buse Bekar: investigation, data curation, writing – original draft. Handan Sevim Akan: conceptualization, investigation, writing – original draft, writing – review & editing, validation, formal analysis, supervision, data curation, resources. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors gratefully acknowledge Dr. Robert William Arpke and Prof. Dr. Yusuf Çetin Kocaefe for their valuable contribution to the language editing and the critical reading of the manuscript; Assoc. Dr. Esin Akbay Çetin and MSc Elçin Tank for their help with the CAM assay. This manuscript is based on the Master's thesis of (Buse Bekar), conducted at (Hacettepe University). Part of this study was previously presented as an oral presentation (29th National Biomedical Science & Technology Symposium, Ankara, Türkiye, 2025). Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.